It has been previously demonstrated that glypican-3 (GPC3) is differentially expressed in hepatocellular carcinomas (HCC), making it a promising target for radiopharmaceutical therapy to treat HCC. At the ongoing meeting of the European Association of Nuclear Medicine in Vienna, researchers from Rayzebio Inc. and Peptidream Inc. presented the preclinical characterization of a novel proprietary peptide binder of GPC3, RAYZ-8009.
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with documented efficacy in non-small-cell lung cancer. However, in most cases, patients develop resistance to this treatment by mechanisms that are not clear in half of the cases. Researchers from Shanghai Pulmonary Hospital presented data on BC-3448, a bispecific antibody targeting EGFR and CD3 aimed to recruit T cells to tumors with high EGFR expression leading to T cell-driven tumor cell killing. The compound presents a stronger binding affinity for EGFR than for CD3 to avoid the development of cytokine release syndrome, which is a safety issue common in CD3-based bispecific antibodies.
Springboarding off the success of its AI-based imaging software for cancer detection, the deep learning-based artificial intelligence (AI) company Lunit Inc. has another AI software, called the Lunit Scope, up its sleeve for which it hopes to gain U.S. FDA approval by 2025.
Researchers from Beijing Inno Medicine Co. Ltd. recently reported preclinical data for the novel liposome encapsulated rosuvastatin calcium candidate, YN-001, being developed for the treatment of atherosclerosis.
South Korean biopharmaceutical firms are facing a harsher climate and an uphill battle both domestically and abroad, amid the larger economic downturn that has slowed everything from new drug approval to dealmaking. At the Global Pharma Key Opinion Leaders (GPKOL) 2023 Symposium held at the El Tower on Sept. 7 in Seocho-gu, Seoul, officials from the industry, government and academia gathered to discuss strategies on bouncing back from the lasting effects of the COVID-19 pandemic.
Conjugated oligoelectrolytes (COEs) have recently emerged as potential broad-spectrum antibiotics with promising selectivity that is irrespective of metabolic state, including dormant and biofilm-associated bacteria. Researchers from National University of Singapore, University of California Santa Barbara, and Walter Reed Army Institute of Research have sought to identify novel cationic antimicrobial COE candidates.
Rapidly evolving artificial intelligence (AI) is effectively resetting all biopharmaceutical companies to the figurative starting line, and collaboration is a key strategy to winning the drug discovery race, an AI-based startup founder said at the Global Bio Conference (GBC) 2023.
Researchers from Bristol Myers Squibb Co. recently discussed the discovery and preclinical characterization of a series of Toll-like receptor 7 (TLR7) agonists with potential as anticancer drug candidates.
RSS
